Meeting
2023 ASCO Annual Meeting
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
Authors
Lisa Bodei
Memorial Sloan Kettering Cancer Center, New York, NY
Lisa Bodei , Petr Kavan , Moishe Liberman , Neil Taunk , Ur Metser , Daniel Juneau , Eileen Mary O'Reilly , Junsheng Ma , Richard Cioci , Albiruni Ryan Abdul Razak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Radiopharmaceuticals
Clinical Trial Registration Number
NCT05432193
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3161)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3161
Abstract #
TPS3161
Poster Bd #
355a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
First Author: Yan Song
Poster
2018 ASCO Annual Meeting
A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher